Menopause, mental health, cardio risk + VMS pipeline advance
Key Questions
What are the links between menopause, mental health, and cardiovascular risk?
Cohort and JAMA data show rises in brain fog and mood issues during menopause. Premature menopause increases coronary heart disease risk by 40%, with racial gaps observed. These findings underscore the need for integrated health screening.
What is the status of Vistagen's refisolone nasal spray for menopause symptoms?
Vistagen received FDA Phase 2 clearance for refisolone nasal spray after Phase 2a results showed an 80% reduction in hot flashes. The FDA's 'study may proceed' letter allows further Phase 2 development for vasomotor symptoms. This advances the VMS pipeline.
What opportunities exist in menopause care based on recent data?
Opportunities include developing screening bundles for brain fog, mood, and cardio risks. Digital therapeutics pilots can generate real-world evidence. These address gaps in mental health and cardiovascular monitoring during menopause.
Cohort/JAMA data: brain fog/mood rise, premature menopause +40% CHD (racial gaps); Vistagen refisolone nasal spray FDA ph2 clearance post 80% hot flash cut (ph2a). Opp: screening bundles, DTx/pilots for RWE.